About AdvanCell
Changing the Course of Cancer Treatment
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston , Massachusetts
- Founded
- 2019
- Company type
- Privately Held
AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
Specialties
- Radiopharmaceuticals
- Radioligand Discovery
- 212Pb
- Biotechnology
- Biopharmaceuticals
- and Changing the Course of Cancer
Company locations
Boston , Massachusetts, US
9-19 MacGregor Pl, Richlands, Queensland 4077, AU
Level 7, 167 Macquarie Street, Sydney, New South Wales 2000, AU
University of Newcastle, Newcastle, NSW, AU
Queensland Centre for Advanced Technologies, Pullenvale, AU
SAN FRANCSICO, CA 94123, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 9,548
- People linked to this company
- 98
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.